Piper Sandler Remains a Buy on CVRx (CVRX)

Piper Sandler analyst Matthew O’Brien maintained a Buy rating on CVRx (CVRX – Research Report) today and set a price target of $15.00. The company’s shares opened today at $9.51.

According to TipRanks, O’Brien is a 4-star analyst with an average return of 5.8% and a 51.84% success rate. O’Brien covers the Healthcare sector, focusing on stocks such as Dexcom, Boston Scientific, and Conmed.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CVRx with a $17.00 average price target, which is a 78.76% upside from current levels. In a report released today, Craig-Hallum also initiated coverage with a Buy rating on the stock with a $23.00 price target.

The company has a one-year high of $33.14 and a one-year low of $9.92. Currently, CVRx has an average volume of 127K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CVRx (CVRX) Company Description:

CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases.